Fostering Cooperation and Strengthening Medical Product Regulatory Systems in the Americas, 38538-38539 [2014-15870]
Download as PDF
38538
Federal Register / Vol. 79, No. 130 / Tuesday, July 8, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
I. Funding Opportunity Description
Food and Drug Administration
93.103
RFA–FD–13–039
[Docket No. FDA–2014–N–0012]
Fostering Cooperation and
Strengthening Medical Product
Regulatory Systems in the Americas
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA), Office of
International Programs (OIP) is
announcing the availability of grant
funds for the support of a single source
cooperative agreement to the Pan
American Health Organization (PAHO)
for fostering cooperation and
strengthening medical product
regulatory systems in the Americas. The
goal of the cooperative agreement is to
build upon existing cooperation
between OIP/FDA and PAHO to foster
regulatory collaboration and strengthen
regulatory capacity throughout the
Americas.
SUMMARY:
Important dates are as follows:
1. The application due date is August
1, 2014.
2. The anticipated start date is
October 1, 2014.
3. The expiration date is August 2,
2014.
DATES:
Submit electronic
applications to: https://www.grants.gov.
For more information, see section III of
the SUPPLEMENTARY INFORMATION section
of this notice.
ADDRESSES:
tkelley on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Charles M. Preston, Office of Strategy,
Partnerships and Analytics, Office of
International Programs, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 3309, Silver Spring,
MD 20993, 301–796–0654; or Kimberly
Pendleton-Chew, Food and Drug
Administration, Division of
Acquisitions and Grants (HFA 500),
5630 Fishers Lane, Rm. 2031, Rockville,
MD 20857, 240–402–7610.
For more information on this funding
opportunity announcement (FOA) and
to obtain detailed requirements, please
refer to the full FOA located at https://
www.fda.gov/InternationalPrograms/
CapacityBuilding/default.htm.
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
16:48 Jul 07, 2014
Jkt 232001
A. Background
PAHO is the Regional Office for the
Americas of the World Health
Organization (WHO). WHO has
responsibility for helping to ensure
access to essential medical products of
assured safety, quality, and efficacy
within its 193 member states. It does so
in three primary areas: (1) Setting global
norms and standards; (2) articulating
evidence-based policy options,
including those relating to regulatory
systems performance; and (3) providing
technical support to national and
regional regulatory authorities and
governments. These activities help to
strengthen regulatory systems which, in
this era of globalization, where the
supply chain of medicines has become
a global network, and as national,
regional, and global health programs
work to scale up access to medicines
and health products, strong regulatory
systems, are imperative.
The necessary constituents of a
medical products regulatory system
have been defined by PAHO and WHO.
They include regulatory frameworks,
marketing authorization, import/export
control and postmarket surveillance,
licensing of manufacturers, inspections,
laboratories, pharmacovigilance, clinical
trials, and vaccine lot release.
Specifically, PAHO helps to strengthen
medical products regulatory systems
through activities that include
disseminating quality norms and
standards, facilitating the exchange of
regulatory information, evaluating
regulatory authorities, providing
training and technical assistance,
distributing scientific materials and
information on aspects of regulation,
strengthening regional monitoring and
surveillance for falsified and
substandard products (including
supporting national pharmacovigilance
programs), and building capacity as a
component of WHO’s prequalification
programs.
In recent years, OIP/FDA has been
actively engaged with PAHO on a
number of areas related to regulatory
systems strengthening. OIP/FDA and
PAHO are currently involved in a 4-year
cooperative agreement which began in
September 2010 that promotes medical
product regulatory system strengthening
in the Americas. The centerpiece of the
agreement is the development of the
Regional Platform for Access and
Innovation of Health Technologies
(PRAIS), an electronic platform for
regulatory exchange. The site was
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
launched by PAHO in 2012 and the
cooperative agreement is managed by
OIP, with additional strategic and
technical guidance provided by a
steering group of FDA Center subject
matter experts. PRAIS includes features
such as communities of practice, where
regulators can share information and
engage in real-time dialogue around
regulatory issues, and an ‘‘observatory’’,
where information on the basic
structures and functions of participating
regulatory authorities is housed.
PAHO envisions PRAIS to be a
cornerstone of its regulatory system
strengthening activities in the Americas.
Beyond the immediate functionalities,
PRAIS is also being used to prioritize
and coordinate activities related to the
Pan American Network for Drug
Regulatory Harmonization. In addition,
PRAIS is being used to develop regional
models for regulatory systems; for
example, data from the observatory have
been used in research to assess strengths
and weaknesses of regulatory systems in
the Caribbean towards a regional
system. Another initiative related to
PRAIS is a secure platform for sharing
non-public information, called
PRAISsec, and FDA has been engaged in
its governance and assessing agency
needs and requirements. At this time,
the platform is not yet built and no nonpublic information has been shared. A
next phase of development for PRAIS
may include global scale-up, which will
enhance the platform’s utility to other
parts of the world that are in critical
need of regulatory information exchange
and capacity building tools.
OIP/FDA entered a similar
cooperative agreement on regulatory
systems strengthening with WHO in
fiscal year (FY) 2014. Activities include
work that WHO is undertaking at the
global level, including advancement of
a member state mechanism on
substandard, spurious, falsified, falselylabeled, and counterfeit medical
products (SSFFC), enhancement of
another FDA-supported cooperative
agreement to develop a global
monitoring system for SSFFC medical
products, and specific work to improve
regulation of active pharmaceutical
ingredients among regulators in WHO’s
member states.
B. Research Objectives
The cooperative agreement
announced in this FOA represents the
further expansion of well-established
collaborations between OIP/FDA and
PAHO in support of data-driven and
science-based public health strategies
and approaches. The objective is to
build upon existing cooperation to
foster regulatory collaboration and
E:\FR\FM\08JYN1.SGM
08JYN1
Federal Register / Vol. 79, No. 130 / Tuesday, July 8, 2014 / Notices
strengthen regulatory capacity
throughout the Americas in ways that
provide benefit and contribution to the
FDA regulatory and public health
mission. This partnership aligns with
FDA’s domestic and global goals of
addressing medical product safety and
quality challenges.
This cooperative agreement will
support collaboration and investigation
in the following areas:
1. Developing and Applying Regional/
Global Norms and Standards
• Enable the sharing of scientific
findings and data through expert
meetings and technical consultations;
• assist member states in the
implementation and subsequent
evaluation of internationally-recognized
standards and guidelines, e.g. WHO
guidelines and standards and those
emerging from standards development
venues such as the International
Conference on Harmonisation of
Technical Requirements for Registration
of Pharmaceuticals for Human Use
(ICH);
• utilize PAHO’s convening power to
engage with relevant stakeholders on
science-based norms and standards; and
• facilitate the alignment and
convergence of standards between
PAHO, other regions, and/or global
bodies.
tkelley on DSK3SPTVN1PROD with NOTICES
2. Researching Regulatory Systems
Performance
• Contribute to the knowledge base of
the current state of medical product
regulation globally, including
challenges, risks, and emerging trends,
and making the business case for
investments in regulatory systems; and
• enable and/or further strengthen the
development of data/information
systems as sources of inputs for
evidence-based regulatory decisions and
actions and enhanced knowledge
management systems, coalitions, and
networks.
3. Providing Technical Support to
Regulatory Systems Strengthening
Efforts and Expand Awareness of the
Role of Regulatory Systems in the
Broader Global Health Development
Framework
• Enable the strengthening of
regulatory systems at the regional and
global levels in such critical domains as:
Regulatory frameworks; marketing
authorization; import/export control
and postmarket surveillance;
inspections; laboratories;
pharmacovigilance; clinical trials and
vaccine lot release; staff development
and training, including the
professionalization of the regulatory
VerDate Mar<15>2010
16:48 Jul 07, 2014
Jkt 232001
workforce; monitoring and evaluation of
product quality; inspection and
surveillance of products throughout the
supply chain; and risk assessment,
analysis, and management; and
• contribute strategies to expand the
knowledge and awareness of the
essential role of regulatory systems
within the broader global health and
development frameworks, including
ways that can leverage existing
initiatives, investments and
partnerships or catalyze new ones.
C. Eligibility Information
This is a single source cooperative
agreement. PAHO is eligible to apply for
this award. PAHO is the Regional Office
for the Americas of WHO. WHO has
responsibility for helping to ensure
access to essential medical products of
assured safety, quality, and efficacy
within its 193 member states. It does so
in three primary areas: (1) Setting global
norms and standards; (2) articulating
evidence-based policy options,
including those relating to regulatory
systems performance; and (3) providing
technical support to national and
regional regulatory authorities and
governments. In recent years, OIP/FDA
has been actively engaged with PAHO
on a number of areas related to
regulatory systems strengthening. OIP/
FDA and PAHO are currently involved
in a 4-year cooperative agreement which
began in September 2010 that promotes
medical product regulatory system
strengthening in the Americas.
II. Award Information/Funds Available
A. Award Amount
This award is contingent upon FDA
appropriations and meritorious
application. FDA/OIP can fund one
award in the amount up to $2 million
for FY 2015 based on available
appropriations.
B. Length of Support
The total project period may not
exceed 5 years. Funding in future years
will be contingent on the availability of
appropriations and successful
performance in the award not to exceed
$2 million per year.
III. Electronic Application,
Registration, and Submission
Only electronic applications will be
accepted. To submit an electronic
application in response to this FOA,
applicants should first review the full
announcement located https://
www.fda.gov/InternationalPrograms/
CapacityBuilding/default.htm. (FDA has
verified the Web site addresses
throughout this document, but FDA is
not responsible for any subsequent
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
38539
changes to the Web sites after this
document publishes in the Federal
Register.) For all electronically
submitted applications, the following
steps are required.
• Step 1: Obtain a Dun and Bradstreet
(DUNS) Number
• Step 2: Register With System for
Award Management (SAM)
• Step 3: Obtain Username & Password
• Step 4: Authorized Organization
Representative (AOR) Authorization
• Step 5: Track AOR Status
• Step 6: Register With Electronic
Research Administration (eRA)
Commons
Steps 1 through 5, in detail, can be
found at https://www07.grants.gov/
applicants/organization_
registration.jsp. Step 6, in detail, can be
found at https://commons.era.nih.gov/
commons/registration/
registrationInstructions.jsp. After you
have followed these steps, submit
electronic applications to: https://
www.grants.gov.
Dated: July 2, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–15870 Filed 7–7–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–N–2014–0865]
Patient-Focused Drug Development for
Idiopathic Pulmonary Fibrosis; Public
Meeting; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA or Agency) is
announcing a public meeting and an
opportunity for public comment on
Patient-Focused Drug Development for
idiopathic pulmonary fibrosis. PatientFocused Drug Development is part of
FDA’s performance commitments made
as part of the fifth authorization of the
Prescription Drug User Fee Act (PDUFA
V). The public meeting is intended to
allow FDA to obtain patient
perspectives on the impact of idiopathic
pulmonary fibrosis on daily life as well
as patient views on treatment
approaches for idiopathic pulmonary
fibrosis.
SUMMARY:
The public meeting will be held
on September 26, 2014, from 1 p.m. to
5 p.m. Registration to attend the meeting
DATES:
E:\FR\FM\08JYN1.SGM
08JYN1
Agencies
[Federal Register Volume 79, Number 130 (Tuesday, July 8, 2014)]
[Notices]
[Pages 38538-38539]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-15870]
[[Page 38538]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0012]
Fostering Cooperation and Strengthening Medical Product
Regulatory Systems in the Americas
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA), Office of
International Programs (OIP) is announcing the availability of grant
funds for the support of a single source cooperative agreement to the
Pan American Health Organization (PAHO) for fostering cooperation and
strengthening medical product regulatory systems in the Americas. The
goal of the cooperative agreement is to build upon existing cooperation
between OIP/FDA and PAHO to foster regulatory collaboration and
strengthen regulatory capacity throughout the Americas.
DATES: Important dates are as follows:
1. The application due date is August 1, 2014.
2. The anticipated start date is October 1, 2014.
3. The expiration date is August 2, 2014.
ADDRESSES: Submit electronic applications to: https://www.grants.gov.
For more information, see section III of the SUPPLEMENTARY INFORMATION
section of this notice.
FOR FURTHER INFORMATION CONTACT: Charles M. Preston, Office of
Strategy, Partnerships and Analytics, Office of International Programs,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm.
3309, Silver Spring, MD 20993, 301-796-0654; or Kimberly Pendleton-
Chew, Food and Drug Administration, Division of Acquisitions and Grants
(HFA 500), 5630 Fishers Lane, Rm. 2031, Rockville, MD 20857, 240-402-
7610.
For more information on this funding opportunity announcement (FOA)
and to obtain detailed requirements, please refer to the full FOA
located at https://www.fda.gov/InternationalPrograms/CapacityBuilding/default.htm.
SUPPLEMENTARY INFORMATION:
I. Funding Opportunity Description
RFA-FD-13-039
93.103
A. Background
PAHO is the Regional Office for the Americas of the World Health
Organization (WHO). WHO has responsibility for helping to ensure access
to essential medical products of assured safety, quality, and efficacy
within its 193 member states. It does so in three primary areas: (1)
Setting global norms and standards; (2) articulating evidence-based
policy options, including those relating to regulatory systems
performance; and (3) providing technical support to national and
regional regulatory authorities and governments. These activities help
to strengthen regulatory systems which, in this era of globalization,
where the supply chain of medicines has become a global network, and as
national, regional, and global health programs work to scale up access
to medicines and health products, strong regulatory systems, are
imperative.
The necessary constituents of a medical products regulatory system
have been defined by PAHO and WHO. They include regulatory frameworks,
marketing authorization, import/export control and postmarket
surveillance, licensing of manufacturers, inspections, laboratories,
pharmacovigilance, clinical trials, and vaccine lot release.
Specifically, PAHO helps to strengthen medical products regulatory
systems through activities that include disseminating quality norms and
standards, facilitating the exchange of regulatory information,
evaluating regulatory authorities, providing training and technical
assistance, distributing scientific materials and information on
aspects of regulation, strengthening regional monitoring and
surveillance for falsified and substandard products (including
supporting national pharmacovigilance programs), and building capacity
as a component of WHO's prequalification programs.
In recent years, OIP/FDA has been actively engaged with PAHO on a
number of areas related to regulatory systems strengthening. OIP/FDA
and PAHO are currently involved in a 4-year cooperative agreement which
began in September 2010 that promotes medical product regulatory system
strengthening in the Americas. The centerpiece of the agreement is the
development of the Regional Platform for Access and Innovation of
Health Technologies (PRAIS), an electronic platform for regulatory
exchange. The site was launched by PAHO in 2012 and the cooperative
agreement is managed by OIP, with additional strategic and technical
guidance provided by a steering group of FDA Center subject matter
experts. PRAIS includes features such as communities of practice, where
regulators can share information and engage in real-time dialogue
around regulatory issues, and an ``observatory'', where information on
the basic structures and functions of participating regulatory
authorities is housed.
PAHO envisions PRAIS to be a cornerstone of its regulatory system
strengthening activities in the Americas. Beyond the immediate
functionalities, PRAIS is also being used to prioritize and coordinate
activities related to the Pan American Network for Drug Regulatory
Harmonization. In addition, PRAIS is being used to develop regional
models for regulatory systems; for example, data from the observatory
have been used in research to assess strengths and weaknesses of
regulatory systems in the Caribbean towards a regional system. Another
initiative related to PRAIS is a secure platform for sharing non-public
information, called PRAISsec, and FDA has been engaged in its
governance and assessing agency needs and requirements. At this time,
the platform is not yet built and no non-public information has been
shared. A next phase of development for PRAIS may include global scale-
up, which will enhance the platform's utility to other parts of the
world that are in critical need of regulatory information exchange and
capacity building tools.
OIP/FDA entered a similar cooperative agreement on regulatory
systems strengthening with WHO in fiscal year (FY) 2014. Activities
include work that WHO is undertaking at the global level, including
advancement of a member state mechanism on substandard, spurious,
falsified, falsely-labeled, and counterfeit medical products (SSFFC),
enhancement of another FDA-supported cooperative agreement to develop a
global monitoring system for SSFFC medical products, and specific work
to improve regulation of active pharmaceutical ingredients among
regulators in WHO's member states.
B. Research Objectives
The cooperative agreement announced in this FOA represents the
further expansion of well-established collaborations between OIP/FDA
and PAHO in support of data-driven and science-based public health
strategies and approaches. The objective is to build upon existing
cooperation to foster regulatory collaboration and
[[Page 38539]]
strengthen regulatory capacity throughout the Americas in ways that
provide benefit and contribution to the FDA regulatory and public
health mission. This partnership aligns with FDA's domestic and global
goals of addressing medical product safety and quality challenges.
This cooperative agreement will support collaboration and
investigation in the following areas:
1. Developing and Applying Regional/Global Norms and Standards
Enable the sharing of scientific findings and data through
expert meetings and technical consultations;
assist member states in the implementation and subsequent
evaluation of internationally-recognized standards and guidelines, e.g.
WHO guidelines and standards and those emerging from standards
development venues such as the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH);
utilize PAHO's convening power to engage with relevant
stakeholders on science-based norms and standards; and
facilitate the alignment and convergence of standards
between PAHO, other regions, and/or global bodies.
2. Researching Regulatory Systems Performance
Contribute to the knowledge base of the current state of
medical product regulation globally, including challenges, risks, and
emerging trends, and making the business case for investments in
regulatory systems; and
enable and/or further strengthen the development of data/
information systems as sources of inputs for evidence-based regulatory
decisions and actions and enhanced knowledge management systems,
coalitions, and networks.
3. Providing Technical Support to Regulatory Systems Strengthening
Efforts and Expand Awareness of the Role of Regulatory Systems in the
Broader Global Health Development Framework
Enable the strengthening of regulatory systems at the
regional and global levels in such critical domains as: Regulatory
frameworks; marketing authorization; import/export control and
postmarket surveillance; inspections; laboratories; pharmacovigilance;
clinical trials and vaccine lot release; staff development and
training, including the professionalization of the regulatory
workforce; monitoring and evaluation of product quality; inspection and
surveillance of products throughout the supply chain; and risk
assessment, analysis, and management; and
contribute strategies to expand the knowledge and
awareness of the essential role of regulatory systems within the
broader global health and development frameworks, including ways that
can leverage existing initiatives, investments and partnerships or
catalyze new ones.
C. Eligibility Information
This is a single source cooperative agreement. PAHO is eligible to
apply for this award. PAHO is the Regional Office for the Americas of
WHO. WHO has responsibility for helping to ensure access to essential
medical products of assured safety, quality, and efficacy within its
193 member states. It does so in three primary areas: (1) Setting
global norms and standards; (2) articulating evidence-based policy
options, including those relating to regulatory systems performance;
and (3) providing technical support to national and regional regulatory
authorities and governments. In recent years, OIP/FDA has been actively
engaged with PAHO on a number of areas related to regulatory systems
strengthening. OIP/FDA and PAHO are currently involved in a 4-year
cooperative agreement which began in September 2010 that promotes
medical product regulatory system strengthening in the Americas.
II. Award Information/Funds Available
A. Award Amount
This award is contingent upon FDA appropriations and meritorious
application. FDA/OIP can fund one award in the amount up to $2 million
for FY 2015 based on available appropriations.
B. Length of Support
The total project period may not exceed 5 years. Funding in future
years will be contingent on the availability of appropriations and
successful performance in the award not to exceed $2 million per year.
III. Electronic Application, Registration, and Submission
Only electronic applications will be accepted. To submit an
electronic application in response to this FOA, applicants should first
review the full announcement located https://www.fda.gov/InternationalPrograms/CapacityBuilding/default.htm. (FDA has verified
the Web site addresses throughout this document, but FDA is not
responsible for any subsequent changes to the Web sites after this
document publishes in the Federal Register.) For all electronically
submitted applications, the following steps are required.
Step 1: Obtain a Dun and Bradstreet (DUNS) Number
Step 2: Register With System for Award Management (SAM)
Step 3: Obtain Username & Password
Step 4: Authorized Organization Representative (AOR)
Authorization
Step 5: Track AOR Status
Step 6: Register With Electronic Research Administration (eRA)
Commons
Steps 1 through 5, in detail, can be found at https://www07.grants.gov/applicants/organization_registration.jsp. Step 6, in
detail, can be found at https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp. After you have followed
these steps, submit electronic applications to: https://www.grants.gov.
Dated: July 2, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-15870 Filed 7-7-14; 8:45 am]
BILLING CODE 4164-01-P